Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Naturally occurring T cell mutations enhance engineered T cell therapies.

Nature - 1 Feb 2024

Garcia Julie, Daniels Jay, Lee Yujin, Zhu Iowis, Cheng Kathleen, Liu Qing, Goodman Daniel, Burnett Cassandra, Law Calvin, Thienpont Chloë, Alavi Josef, Azimi Camillia, Montgomery Garrett, Roybal Kole T, Choi Jaehyuk

Abstract excerpt

Adoptive T cell therapies have produced exceptional responses in a subset of patients with cancer. However, therapeutic efficacy can be hindered by poor T cell persistence and function1. In human T cell cancers, evolution of the disease positively selects for mutations that improve fitness of T cells in challenging situations analogous to those faced by therapeutic T cells. Therefore, we reasoned that these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CARD Signaling Adaptor Proteins
Share to CD4-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytokines

Share to Guanylate Cyclase

Share to Immunotherapy, Adoptive

Share to Lymphoma, T-Cell, Cutaneous

Share to Phosphatidylinositol 3-Kinases

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 38326614
DOI: 10.1038/s41586-024-07018-7
PMCID: PMC11573425

Genes

CARD11
BCL10
CD4
MALT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Naturally occurring T cell mutations enhance engineered T cell therapies.PMID 38326614Read ↗

Emerging Cellular Therapies for CancerSemantic proximity Read ↗

Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens.Semantic proximity Read ↗

CARD11 signaling regulates CD8+ T cell tumoricidal function.Semantic proximity Read ↗

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapySemantic proximity Read ↗

Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cellsSemantic proximity Read ↗

Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapySemantic proximity Read ↗

The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell MalignancySemantic proximity Read ↗

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.Semantic proximity Read ↗

A practical workflow for CAR screening in primary T cells using fitness-guided design and mRNA electroporationSemantic proximity Read ↗

Genome Editing in Engineered T Cells for Cancer ImmunotherapySemantic proximity Read ↗

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerSemantic proximity Read ↗

Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.